Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892905 | 0.74 | HSD17B10 (0.34) | ALDH1A1HSD17B10 | |
| SCHEMBL9902755 | 0.74 | DYRK1A (0.39) | ALDH1A1HSD17B10 | |
| SCHEMBL1892659 | 0.74 | KDM4E (0.46) | ALDH1A1HSD17B10 | |
| SCHEMBL21958562 | 0.74 | DAO (0.32) | ALDH1A1HSD17B10 | |
| SCHEMBL1887253 | 0.74 | ALDH1A1 (0.31) | ALDH1A1HSD17B10 | |
| SCHEMBL23872468 | 0.71 | NPC1 (0.35) | — | |
| SCHEMBL17901837 | 0.71 | DAO (0.31) | — | |
| SCHEMBL12909524 | 0.69 | IRAK4 (0.34) | ALDH1A1 | |
| SCHEMBL19756503 | 0.69 | DYRK1A (0.33) | — | |
| SCHEMBL12689671 | 0.69 | MEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20060199801-A1 | Heterobicyclic compounds used as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1620436-A1 | HETEROBICYCLIC COMPOUNDS USED AS FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092175-A1 | HETEROBICYCLIC COMPOUNDS USED AS FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199801-A1 | Heterobicyclic compounds used as fungicides | CBR3, CBR1, CYP2A6 | ALDH1A1 1504/4885HSD17B10 601/4885 |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | ALDH1A1 1397/4885HSD17B10 4444/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALDH1A1 1397/4885HSD17B10 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.